Additional file 1 of Usefulness of procalcitonin at admission as a risk-stratifying biomarker for 50-day in-hospital mortality among patients with community-acquired bloodstream infection: an observational cohort study
Creators: name: Oussalah, Abderrahim
name: Callet, Jonas
name: Manteaux, Anne-Elisabeth
name: Thilly, Nathalie
name: Jay, Nicolas
name: Guéant, Jean-Louis
name: Lozniewski, Alain
Publisher: name: figshare
Year: 2023
Subjects: subject: Medicine
subject: Neuroscience
subject: Biotechnology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: Immunology
subject: FOS: Clinical medicine
subject: Cancer
subject: Science Policy
subject: 60506 Virology
subject: FOS: Biological sciences
subject: Computational Biology

description: Additional file 1: Supplemental methods. Supplemental Table S1. Probit regression analysis for the propensity score predicted by the logistic regression model as the dose variable and the risk of 50-day in-hospital mortality as the response variable. Supplemental Table 2. Association between plasma procalcitonin level at admission and all-cause 50-day mortality in multivariable logistic regression analysis. Supplemental Table S3. Kaplan-Meier analysis reporting the probability of survival without in-hospital mortality according to the ROC-defined plasma procalcitonin threshold (&gt; 4.24 ng/mL) at baseline. Supplemental Table S4. Hazard ratios and 95% confidence interval for the pairwise comparison of survival probabilities without in-hospital mortality according to the ROC-defined plasma procalcitonin threshold (&gt; 4.24 ng/mL) at baseline. Supplemental Table S5. Association between plasma procalcitonin level at admission and all-cause in-hospital mortality in multivariable Cox proportional-hazards regression. Supplemental Table S6. Distribution of procalcitonin values according to procalcitonin quartiles. Supplemental Table S7. Kaplan-Meier analysis reporting the probability of survival without in-hospital mortality in the 452 studied patients according to baseline plasma procalcitonin quartiles. Supplemental Table S8. Hazard ratios and 95% confidence interval for the pairwise comparison of survival probabilities without in-hospital mortality according to baseline procalcitonin quartiles. Supplemental Figure S1. Flow diagram of patient selection. Supplemental Figure S2. (A) Kaplan-Meier analysis reporting the probability of survival without in-hospital mortality according to the ROC-defined plasma troponin threshold (&gt; 0.05 ng/mL) at baseline; (B) Kaplan-Meier analysis reporting the probability of survival without in-hospital mortality according to the ROC-defined plasma lactates threshold (&gt; 4.24 ng/mL) at baseline. Supplemental Figure S3. Probit sigmoid dose-response curve showing the propensity score predicted by the logistic regression model as the dose variable and the risk of 50-day in-hospital mortality as the response variable. The red line shows the probability and corresponding dose. The dashed curves represent the 95% confidence interval for the respective dose. The dose and 95% confidence interval corresponding with a particular probability are taken from a horizontal line at that probability level. Supplemental Figure S4. (A) Kaplan-Meier ainalysis reporting the probability of survival without in-hospital mortality in the 452 studied patients. The dashed lines represent the 95% confidence interval of the survival probabilities; (B) Kaplan-Meier analysis reporting the probability of survival without in-hospital mortality according to the ROC-defined plasma procalcitonin threshold (&gt; 4.24 ng/mL) at baseline.